| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OMCL | Common Stock | Award | $0 | +19K | +55.84% | $0.00 | 53.1K | Mar 14, 2022 | Direct | F1 |
| transaction | OMCL | Common Stock | Tax liability | -$293K | -2.24K | -4.21% | $131.21 | 50.9K | Mar 14, 2022 | Direct | F2 |
| transaction | OMCL | Common Stock | Sale | -$336K | -2.53K | -4.96% | $133.11 | 48.4K | Mar 16, 2022 | Direct | F3, F4 |
| holding | OMCL | Common Stock | 43.6K | Mar 14, 2022 | Direct |
| Id | Content |
|---|---|
| F1 | Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 9,520 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 19,040 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022. |
| F2 | Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units. |
| F3 | This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9,2021. |
| F4 | The price reported in Column 4 is an exact price of $133.11 for all shares sold. |